Creador and Leeford Healthcare: Reported talks: about ₹800 Cr for about
· By Abhinav
Leeford Healthcare management at a product launch · Image: Indian Pharma Post
Independent report content
STATUS
TALKS ONLY. All coverage is from the Economic Times via Venture Intelligence (4 Aug), Digital Health News and Medical Dialogues (8 Aug). No signing, closing or company confirmation was found
TARGET
Leeford Healthcare Ltd, Ludhiana, unlisted branded-generics and pharma company founded 2006 · founder Jiwan Lal Gupta, reportedly with nearly 88% held by the family
INVESTOR
Creador, Kuala Lumpur-based private equity firm founded 2011 · Creador VI closed at US$930m (Jan 2025) against a US$750m target
REPORTED TERMS
About ₹800 Cr for about 10% · valuation ₹8,000–8,500 Cr · primary versus secondary split and use of money not reported
FINANCIALS (FY25)
Operating income about ₹1,718 Cr · PAT about ₹240 Cr (Venture Intelligence, citing ET) · other sources give ₹1,500–1,750 Cr or ₹2,000 Cr turnover
OPERATIONS
1,950+ products in 75+ therapeutic categories, 7+ plants, 12 lakh+ pharmacies, 5,000+ staff, exports to about 10–11 countries (2025 promotional figures)
COMPARABLE
Creador bought about 7% of La Renon Healthcare in Dec 2025 at an implied ₹11,000 Cr
CONFLICT
Medical Dialogues calls this Leeford's first outside equity; Venture Intelligence reports about US$88m from TA Associates in 2019
THE ACCESS POINT
Leeford is unlisted and no deal has been confirmed. There is no way for outside investors to buy into it directly.
Executive decision summary
THE BOTTOM LINE
Creador, a Malaysia-based private equity firm, is reported to be in talks to invest about ₹800 crore for about 10% of Leeford Healthcare, a Ludhiana drug maker, at a valuation of ₹8,000 to ₹8,500 crore. The reports come from the Economic Times through Venture Intelligence on 4 August 2026 and from Medical Dialogues and Digital Health News in the following days. Neither company has confirmed, no filing exists and the reports do not say whether the money is new capital or a sale by the founder family. Leeford had operating income of about ₹1,718 crore and a profit of about ₹240 crore in FY25, according to the ET figures, which puts the price at about 33 to 35 times profit. Sources also disagree on whether this would be Leeford's first outside investor. This note is therefore about reported talks and what the numbers imply, not a completed deal.
WHICH INVESTOR
Leeford fits a watch-list IF you track mid-cap pharma private equity and want to see whether the talks become a signed deal.
Wait IF you need a confirmed investment, a split between new and existing shares or an EBITDA figure: none was found.
COMFORT FIT
Branded generics = off-patent medicines sold under the company's own brand name and promoted to doctors.
Valuation = the total value put on the company. ₹800 Cr for 10% implies ₹8,000 Cr.
Primary versus secondary = new money into the company versus a sale by existing holders.
In talks = discussions are reported but nothing has been agreed or announced by the parties.
THE RUPEIA NUMBER
33x to 35x. The reported valuation of ₹8,000–8,500 Cr divided by FY25 profit of about ₹240 Cr, if the ET profit figure is right.
1 CLAIM REGISTER: EVIDENCE GRADING
Claim
Source
Grade
Rupeia assessment
Creador in talks to invest about ₹800 Cr for about 10%
Venture Intelligence (4 Aug, citing ET); Medical Dialogues (8 Aug); Digital Health News
C
Reported talks, unconfirmed
Valuation ₹8,000–8,500 Cr
Medical Dialogues; DHN
C
Body gives a range; Venture Intelligence states none
FY25 operating income about ₹1,718 Cr, PAT about ₹240 Cr
Venture Intelligence citing ET
D
Single source
First external equity since 2006
Medical Dialogues; DHN
D
Conflicts with a TA Associates report
US$88m from TA Associates in Oct 2019
Venture Intelligence
D
Single source; two searches found no other
Promoter holding about 88%
Medical Dialogues; DHN
D
Not checked against a shareholding filing
2 THE REPORTED TERMS AND WHAT THEY IMPLY
Leeford Healthcare's office · Image: Digital Health News
Item
Detail
Amount and stake
About ₹800 Cr for about 10%
Valuation
₹8,000–8,500 Cr (headline ₹8,500 Cr)
Seller or new money
Not reported
Reports
Venture Intelligence 4 Aug 2026; Digital Health News (updated 4 Aug); Medical Dialogues 8 Aug
Use of money
Not reported
Calculation (Rupeia)
Result
Implied valuation at ₹800 Cr for 10%
₹800 Cr ÷ 10% = ₹8,000 Cr
Stake at the ₹8,500 Cr valuation
₹800 Cr ÷ ₹8,500 Cr = 9.4%
Price to earnings (FY25 PAT ₹240 Cr)
₹8,000 Cr = 33.3x; ₹8,500 Cr = 35.4x
Price to operating income (₹1,718 Cr)
4.7x to 4.9x
PAT margin on operating income
₹240 Cr ÷ ₹1,718 Cr = 14.0%
Promoter stake after a 10% sale, if about 88% now
88% − 10% = 78% if all secondary; 88% × 0.9 = 79.2% if all primary
RUPEIA READ
The deal size is modest for the target: 10% of a company worth about ₹8,000 crore. A minority stake at 33 to 35 times profit says the investor is paying for growth and a clean balance sheet, not for control. The reported figures cannot show whether the price is high or low, because no EBITDA, debt or FY26 number was found.
3 WHAT LEEFORD IS
Item
Detail
Source quality
Business
Ludhiana company founded 2006 in branded and generic pharma; divisions include Cosmacia (personal care), Esencia and Medisciences (nephrology and urology)
DHN; company site
Scale (promotional, May 2025)
1,950+ products; 75+ therapeutic categories; 7+ manufacturing units; 12 lakh+ pharmacies and 5 lakh+ general stores; 5,000+ staff; exports to over 11 countries
Mumbai Messenger; the corporate site says 10 overseas destinations
₹200 Cr over three years ≈ ₹67 Cr a year, about 4% of operating income
Staff productivity
₹1,718 Cr ÷ 5,000 staff ≈ ₹34 lakh of income per person (promotional headcount)
RUPEIA READ
Leeford's public profile is promotional, and the financial figures differ by source. The most useful figure is the ET one, but it is a single source and a filing has not been seen. Promoter holding near 88% means the founder family still controls the company, which is typical for a family-owned manufacturer at this stage.
4 THE INVESTOR: CREADOR'S RECORD AND POWDER
Item
Detail
Source
Creador VI
Closed at US$930m against a US$750m target, reported as hard-capped; investors include ADB, IFC and FinDev Canada
Dakota, 22 Jan 2025
Earlier funds
Fund IV about US$565m (above a US$550m hard cap); Fund V US$700m per PitchBook; over US$3.1bn across six funds per one profile
Dakota; PitchBook
Exits
40 per PitchBook against 7 per CB Insights; counts conflict
Paid data not accessed
La Renon Healthcare
About 7% bought from the promoter and Peak XV, announced 8 Dec 2025; reported about ₹770 Cr; WhiteOak and Siguler Guff about 3% for about ₹330 Cr; implied value about ₹11,000 Cr; earlier value about ₹8,000 Cr (Feb 2025)
DealStreetAsia; The Star; ET-based summaries
Other healthcare
Paras Healthcare secondary (Apr 2025); a minority stake in an Indian hospital chain
₹11,000 Cr ÷ ₹8,000 Cr − 1 = 37.5% in about ten months
RUPEIA READ
If both deals close, Creador would put about 17% of its sixth fund into two Indian pharma companies in eight months, each at a roughly similar ticket. That is a concentrated sector bet for a fund described as focused on South and Southeast Asia more broadly, and it fits the wider 2026 pattern of private equity buying minority stakes in profitable mid-cap pharma.
5 THE 2026 PHARMA DEAL CONTEXT
Deal
Detail
Source quality
ChrysCapital and Novartis India
70.68% for about ₹1,446 Cr; agreed Feb 2026 (Report 56)
Press
Warburg Pincus and Integrace
About ₹1,200 Cr; one report says acquired in July 2026, another pending
Conflicting
Warburg Pincus and Maneesh Pharma
Formulations business, ₹1,600–1,800 Cr; advanced discussions in March 2026; no close found
Press
Quadria-led consortium and Samarth Lifesciences
80–85% at about ₹4,500 Cr valuation; under consideration in April 2026
Medical Dialogues
RMB Capitalworks and Biodeal Pharma
₹385 Cr raise, Aug 2026; stake undisclosed
Press
Anupam Rasayan and Bliss GVS
Control for about ₹1,750 Cr (Report 57)
Press
RUPEIA READ
A mid-cap pharma investor in 2026 has many deals to compare. The Leeford price of 33 to 35 times profit is not obviously out of line with the sector, but without EBITDA or growth figures, the comparison to peers on a multiple of operating profit cannot be made.
6 RISKS, SCENARIOS AND CHECKLIST
Risk
Evidence
Severity
Kill condition
Deal may not happen
Talks only; no confirmation or filing
HIGH
Talks lapse
Single-source financials
FY25 income and profit from one report
HIGH
Filings show lower figures
Family-business governance
Promoter holding about 88%; family directors
MEDIUM
Related-party issues
Valuation
33–35x profit with no EBITDA data
MEDIUM
Growth below expectation
Conflicting history
First-investor claim vs TA Associates 2019 report
LOW
Earlier investor terms limit rights
Promotional data
Reach and product figures from marketing material
MEDIUM
Operating data differs
Scenario
What happens
Outcome
Bull
Deal signs at about ₹8,000–8,500 Cr; capital funds new divisions
Growth phase
Base
Deal signs later at a lower price or smaller stake
Modest minority stake
Bear
Talks fail
Leeford continues as a family-owned company
Investor class
Fit
Why
Pharma private-equity watcher
FIT
Fits a clear 2026 pattern of minority stakes
Listed-market investor
INFORMATIONAL
Valuation reference for listed mid-cap pharma
Retail investor
NOT AVAILABLE
Company is unlisted and no deal is confirmed
Rupeia does not recommend buying or selling any security and is not a SEBI-registered investment adviser or research analyst. This note describes reported talks. Open items are confirmation, the primary-secondary split and Leeford's EBITDA.
7 KEY TERMS USED IN THIS REPORT
The terms below are used in this report. Each is explained in plain words.
Term
Meaning
Branded generics
Off-patent medicines sold under a company's own brand name.
Minority stake
A holding below 50% that does not give control.
Valuation
The total value placed on a company; implied by price paid for a share of it.
Primary and secondary
New money for the company versus sale by existing holders.
Hard cap
A ceiling a fund sets on its total size.
Implied value
The value of 100% of a company calculated from a price paid for a part.
Frequently asked questions
Has Creador invested in Leeford Healthcare?
Not on the sources read. Reports from 4 to 8 August 2026 say Creador is in talks; no signing or closing has been reported and neither company has confirmed.
What are the reported terms?
About ₹800 crore for about 10% of Leeford at a valuation of ₹8,000 to ₹8,500 crore.
What does Leeford earn?
FY25 operating income of about ₹1,718 crore and profit of about ₹240 crore according to the Economic Times via Venture Intelligence. Other sources give different revenue figures.
Who owns Leeford?
Founder Jiwan Lal Gupta and family, reportedly holding nearly 88%, according to Medical Dialogues and Digital Health News.
What did Creador do in La Renon Healthcare?
It bought about 7% from the promoter and Peak XV, announced on 8 December 2025, at an implied company value of about ₹11,000 crore.
Is this Leeford's first outside investment?
Two outlets say so, but Venture Intelligence reports about US$88 million from TA Associates in October 2019. The sources conflict.
Source log
Medical Dialogues: Creador in talks to invest ₹800 crore in Leeford Healthcare for 10% stake at ₹8,500 crore valuation
Venture Intelligence: Creador in talks to invest ₹800 Cr in Leeford Healthcare
Digital Health News: Creador eyes ₹800 Cr bet on Leeford Health
Indian Pharma Post: Leeford Healthcare bets ₹200 crore on orthopedic and mobility aids
Tofler: Leeford Healthcare Ltd company page
DealStreetAsia: Creador acquires 7% stake in India's La Renon Healthcare from promoter, Peak XV
Dakota: Creador closes sixth flagship fund oversubscribed at US$930M
DISCLAIMER
This document is published strictly for informational, educational and academic record-keeping purposes. The publisher is not a SEBI Registered Investment Adviser (RIA) or Research Analyst (RA). It does not constitute personal investment advice, a financial recommendation, or an offer or solicitation to buy, sell or subscribe to any securities. Investments in the securities market are subject to market risks. Read all related documents carefully before investing.